Status:
COMPLETED
Fenofibrate and Pharmacogenetic Impact in Dyslipidemia
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
Laval University
Conditions:
Dyslipidemia
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and c...
Detailed Description
The investigators seek to screen over 200 subjects for select candidate genes to serve as a source of subjects which may participate in a genotype guided investigation as to the predictability of resp...
Eligibility Criteria
Inclusion
- 18-75 year old
- Be willing to participate in the study and attend the scheduled clinic exams
- Consent to taking lipid lowering therapy for 4 weeks and if necessary discontinue lipid lowering agents for a period of 8 weeks
Exclusion
- \<18 years of age
- History of liver, kidney, pancreas, pancreatitis, gall bladder disease or malabsorption (Crohn's disease etc.)
- Use of insulin or currently taking warfarin
- Pregnant women or women of childbearing potential not using an acceptable form of contraception
- History of an allergy or hypersensitivity to fenofibrate
- Investigational drug use within 30 days of the study
- A disease that, in the opinion, of the PI, would put the subject at risk during the study
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00613613
Start Date
January 1 2008
End Date
December 1 2013
Last Update
January 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455